This increases the concern about using benzodiazepines within a psychiatric setting where no reversing agent can practicably be given. The risk of respiratory depression appears to be significantly increased when particular benzodiazepines such as clonazepam are prescribed. In view of this incident, our trust changed the maximum dose of clonazepam given and obtained unlicensed lorazepam injection from the USA for adolescent patients. Footnotes Inhibitors,research,lifescience,medical Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Conflict of interest statement:

The authors declare no conflicts of interest in preparing this article. Contributor Information Jonathan Channing, Specialty Registrar (CT2) in Forensic Adolescent Psychiatry, Bluebird House, Tatchbury Mount, Calmore, Southampton SO40 2RZ, UK. Simon Hill, Consultant Inhibitors,research,lifescience,medical Adolescent

Forensic Psychiatrist, Bluebird House, Tatchbury Mount, Calmore, Southampton, UK. Marion Wetherill, Locality Lead Pharmacist, Bluebird House, Tatchbury Mount, Calmore, Southampton, UK. Oliver White, Inhibitors,research,lifescience,medical Consultant Child and Adolescent Forensic Psychiatrist, Bluebird House, Tatchbury Mount, Calmore, Southampton, UK.
Depressive illness selleck chem affects a significant proportion of the population. It has been reported to have a 1-year prevalence of 3–5% [Hasin et al. 2005; Waraich et al. 2004] and a lifetime prevalence varying from 10 to 30% [Hasin et al. 2005; Waraich Inhibitors,research,lifescience,medical et al. 2004]. Depression is ranked by the World Health Organization as the third highest

cause of disability across the world and it is projected to become the second by 2020 [Murray and Lopez, 1997; World Bank, 2004]. Furthermore depressive illness poses a significant financial burden to society: in 2000 depression in adults cost the UK £9 billion, including direct and indirect costs. Treatment of depression is not always effective. Only a third of patients achieve full remission after their first antidepressant treatment in naturalistic Inhibitors,research,lifescience,medical conditions [Rush et al. 2006]. More effective treatments are therefore required and to achieve this it is important to further understand the biology underpinning depressive illness. A possible target for future treatment of depression is the hypothalamic–pituitary–adrenal Brefeldin_A (HPA) axis and the release of its major final hormone, cortisol. In this paper we review the evidence for the use of metyrapone, a cortisol synthesis inhibitor, for the treatment of treatment-resistant depression (TRD). Other reviews have examined the evidence of antiglucocorticoids in depressive illness (for instance (Gallagher et al., 2008)). To the authors knowledge this is the first review that focuses on the use of metyrapone in depressive illness. Background The hypothalamic–pituitary–adrenal axis The HPA axis is a neuroendocrine system which incorporates the hypothalamus, the pituitary and the adrenal cortex.